217 related articles for article (PubMed ID: 24664503)
1. Clostridium difficile extracytoplasmic function σ factor σV regulates lysozyme resistance and is necessary for pathogenesis in the hamster model of infection.
Ho TD; Williams KB; Chen Y; Helm RF; Popham DL; Ellermeier CD
Infect Immun; 2014 Jun; 82(6):2345-55. PubMed ID: 24664503
[TBL] [Abstract][Full Text] [Related]
2. Lysozyme Resistance in Clostridioides difficile Is Dependent on Two Peptidoglycan Deacetylases.
Kaus GM; Snyder LF; Müh U; Flores MJ; Popham DL; Ellermeier CD
J Bacteriol; 2020 Oct; 202(22):. PubMed ID: 32868404
[No Abstract] [Full Text] [Related]
3. The Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σV in Response to Lysozyme.
Woods EC; Nawrocki KL; Suárez JM; McBride SM
Infect Immun; 2016 Jun; 84(6):1902-1916. PubMed ID: 27068095
[TBL] [Abstract][Full Text] [Related]
4. PrsW is required for colonization, resistance to antimicrobial peptides, and expression of extracytoplasmic function σ factors in Clostridium difficile.
Ho TD; Ellermeier CD
Infect Immun; 2011 Aug; 79(8):3229-38. PubMed ID: 21628514
[TBL] [Abstract][Full Text] [Related]
5. Peptidoglycan analysis reveals that synergistic deacetylase activity in vegetative
Coullon H; Rifflet A; Wheeler R; Janoir C; Boneca IG; Candela T
J Biol Chem; 2020 Dec; 295(49):16785-16796. PubMed ID: 32978253
[No Abstract] [Full Text] [Related]
6. Activation of the Extracytoplasmic Function σ Factor σ
Pannullo AG; Ellermeier CD
mSphere; 2022 Apr; 7(2):e0009222. PubMed ID: 35317618
[TBL] [Abstract][Full Text] [Related]
7. Activation of the extracytoplasmic function σ factor σ
Ho TD; Ellermeier CD
Curr Opin Microbiol; 2022 Feb; 65():162-166. PubMed ID: 34894542
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a bacterial receptor for lysozyme: binding of lysozyme to the anti-σ factor RsiV controls activation of the ecf σ factor σV.
Hastie JL; Williams KB; Sepúlveda C; Houtman JC; Forest KT; Ellermeier CD
PLoS Genet; 2014 Oct; 10(10):e1004643. PubMed ID: 25275625
[TBL] [Abstract][Full Text] [Related]
9. Activation of the extracytoplasmic function σ factor σ
Ho TD; Ellermeier CD
Mol Microbiol; 2019 Aug; 112(2):410-419. PubMed ID: 31286585
[TBL] [Abstract][Full Text] [Related]
10. Bacillus subtilis σ(V) confers lysozyme resistance by activation of two cell wall modification pathways, peptidoglycan O-acetylation and D-alanylation of teichoic acids.
Guariglia-Oropeza V; Helmann JD
J Bacteriol; 2011 Nov; 193(22):6223-32. PubMed ID: 21926231
[TBL] [Abstract][Full Text] [Related]
11. The Bacillus subtilis extracytoplasmic function σ factor σ(V) is induced by lysozyme and provides resistance to lysozyme.
Ho TD; Hastie JL; Intile PJ; Ellermeier CD
J Bacteriol; 2011 Nov; 193(22):6215-22. PubMed ID: 21856855
[TBL] [Abstract][Full Text] [Related]
12. Signal Peptidase Is Necessary and Sufficient for Site 1 Cleavage of RsiV in Bacillus subtilis in Response to Lysozyme.
Castro AN; Lewerke LT; Hastie JL; Ellermeier CD
J Bacteriol; 2018 Jun; 200(11):. PubMed ID: 29358498
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
14. Improving the reproducibility of the NAP1/B1/027 epidemic strain R20291 in the hamster model of infection.
Kelly ML; Ng YK; Cartman ST; Collery MM; Cockayne A; Minton NP
Anaerobe; 2016 Jun; 39():51-3. PubMed ID: 26946361
[TBL] [Abstract][Full Text] [Related]
15. The HtrA-like protease CD3284 modulates virulence of Clostridium difficile.
Bakker D; Buckley AM; de Jong A; van Winden VJ; Verhoeks JP; Kuipers OP; Douce GR; Kuijper EJ; Smits WK; Corver J
Infect Immun; 2014 Oct; 82(10):4222-32. PubMed ID: 25047848
[TBL] [Abstract][Full Text] [Related]
16. Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile.
Spigaglia P; Barbanti F; Mastrantonio P
Antimicrob Agents Chemother; 2008 Feb; 52(2):770-3. PubMed ID: 18070963
[TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile infection: new developments in epidemiology and pathogenesis.
Rupnik M; Wilcox MH; Gerding DN
Nat Rev Microbiol; 2009 Jul; 7(7):526-36. PubMed ID: 19528959
[TBL] [Abstract][Full Text] [Related]
18. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Carman RJ; Boone JH; Grover H; Wickham KN; Chen L
Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175
[TBL] [Abstract][Full Text] [Related]
19. Global analysis of the sporulation pathway of Clostridium difficile.
Fimlaid KA; Bond JP; Schutz KC; Putnam EE; Leung JM; Lawley TD; Shen A
PLoS Genet; 2013; 9(8):e1003660. PubMed ID: 23950727
[TBL] [Abstract][Full Text] [Related]
20. The extracytoplasmic function sigma factor SigV plays a key role in the original model of lysozyme resistance and virulence of Enterococcus faecalis.
Le Jeune A; Torelli R; Sanguinetti M; Giard JC; Hartke A; Auffray Y; Benachour A
PLoS One; 2010 Mar; 5(3):e9658. PubMed ID: 20300180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
